Related Experiment Videos
[Hypolipemic treatment in prevention of secondary ischemic heart disease]
1Kliniki Choroby Wieńcowej, Instytutu Kardiologii, Collegium Medicum, Uniwersytetu Jagiellońskiego w Krakowie.
Abstract:
Available evidence indicating a possibility to inhibit the development of atherosclerosis and to reduce the mortality rate due to associated diseases in humans forms the rationale behind prevention of cardiovascular diseases. It consists of simultaneous modification of all concomitant risk factors including treatment of lipid disorders. Reduction of increased LDL cholesterol and TG levels is associated with a number of clinical benefits. It improves arterial endothelial function and stabilizes atheromatous plaque, which is reflected in the improved clinical, angiographic and hemostatic picture. Multiple studies have revealed a decreased rate of cardiac events and cardiovascular mortality in patients treated for lipid disorders. Furthermore, progression of atherosclerotic lesions has been shown to be inhibited. Before initiation of the therapy for lipid disorders taget LDL cholesterol level should be determined depending on the patient's risk group. In patients with known coronary artery disease or peripheral atherosclerosis (high risk group) it is desirable to reach LDL cholesterol level below 100 mg/dl and TG below 200 mg/dl. Basic approach to the therapy of lipid disorders both in primary and secondary prevention includes, modifications in the life style, especially dietary habits which may result in a mean of 10 to 20% decrease of LDL cholesterol and TG. When dietary modifications are ineffective it is recommended to use combined therapy but with a high degree of caution.
Insights
Preventing cardiovascular diseases involves managing lipid disorders to reduce atherosclerosis. Lowering LDL cholesterol and triglycerides offers significant clinical benefits, improving patient outcomes and reducing mortality.
Area of Science:
- Cardiology
- Metabolic Disorders
- Preventive Medicine
Context:
- Cardiovascular diseases (CVDs) pose a significant health burden, with atherosclerosis being a primary underlying pathology.
- Effective prevention strategies necessitate addressing multiple risk factors, including dyslipidemia (abnormal blood lipid levels).
- Managing lipid disorders is crucial for inhibiting atherosclerosis progression and reducing CVD-related mortality.
Purpose:
- To outline the rationale and clinical benefits of managing lipid disorders in the prevention of cardiovascular diseases.
- To establish target lipid levels for different patient risk groups.
- To describe therapeutic approaches for lipid disorders, emphasizing lifestyle modifications and cautious use of combined therapies.
Summary:
- Reducing elevated low-density lipoprotein (LDL) cholesterol and triglycerides offers substantial clinical advantages, including improved endothelial function and plaque stabilization.
- Studies demonstrate that treating lipid disorders decreases cardiac events and cardiovascular mortality, while inhibiting atherosclerotic lesion progression.
- Therapeutic goals for LDL cholesterol (<100 mg/dL) and triglycerides (<200 mg/dL) should be tailored to patient risk, with lifestyle changes being the primary intervention.
Impact:
- This evidence supports the integration of lipid management into comprehensive cardiovascular disease prevention programs.
- Achieving target lipid levels can lead to improved clinical outcomes, reduced healthcare utilization, and enhanced patient quality of life.
- Highlights the importance of personalized risk assessment in guiding lipid-lowering therapies.